Relmada Therapeutics Inc Total Assets
Relmada Therapeutics Inc total assets. Based on the latest financial reports, Relmada Therapeutics Inc (RLMD) holds total assets worth $235.36 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see RLMD operating cash flow for how efficiently the company converts equity into cash flow.
Total Assets of Relmada Therapeutics Inc (2012–2025)
Total assets of Relmada Therapeutics Inc from 2012 to 2025. This chart illustrates how Relmada Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See RLMD stock price for real-time trading data and today's change.
Relmada Therapeutics Inc - Asset Composition Analysis
Relmada Therapeutics Inc Total Assets Breakdown (December 2025)
Relmada Therapeutics Inc total assets breakdown as of December 2025. Relmada Therapeutics Inc's total assets of $235.36 Million consist of 100.0% current assets and 0.0% non-current assets. Explore RLMD net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Relmada Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Relmada Therapeutics Inc's current assets represent 100.0% of total assets in 2025, a decrease from 100.0% in 2012.
- Cash Position: Cash and equivalents constituted 3.7% of total assets in 2025, down from 48.8% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Relmada Therapeutics Inc Competitors by Total Assets
Key competitors of Relmada Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.98 Billion |
Relmada Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.26 | 5.29 | 7.95 |
| Quick Ratio | 18.26 | 5.29 | 7.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $222.45 Million | $22.43 Million | $96.78 Million |
Relmada Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Relmada Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.03 |
| Latest Market Cap to Assets Ratio | 3.84 |
| Asset Growth Rate (YoY) | 105.2% |
| Total Assets | $94.00 Million |
| Market Capitalization | $360.82 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Relmada Therapeutics Inc's assets at a significant premium (3.84x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Relmada Therapeutics Inc's assets grew by 105.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Relmada Therapeutics Inc (2012–2025)
The table below shows the annual total assets of Relmada Therapeutics Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $94.00 Million | +105.17% |
| 2024-12-31 | $45.82 Million | -53.03% |
| 2023-12-31 | $97.55 Million | -36.20% |
| 2022-12-31 | $152.91 Million | -31.53% |
| 2021-12-31 | $223.33 Million | +88.96% |
| 2020-12-31 | $118.19 Million | +0.90% |
| 2019-12-31 | $117.14 Million | +3742.95% |
| 2018-12-31 | $3.05 Million | +7.44% |
| 2017-12-31 | $2.84 Million | -72.31% |
| 2016-12-31 | $10.24 Million | -58.00% |
| 2015-12-31 | $24.39 Million | 0.00% |
| 2014-12-31 | $24.39 Million | -5.32% |
| 2014-06-30 | $25.76 Million | 0.00% |
| 2013-12-31 | $25.76 Million | +140275.12% |
| 2012-12-31 | $18.35K | -- |
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more